KTI 2338
Alternative Names: KTI-2338Latest Information Update: 28 Apr 2025
At a glance
- Originator Massachusetts General Hospital; National Center for Advancing Translational Sciences
- Developer Keros Therapeutics
- Class Antianaemics; Small molecules
- Mechanism of Action ACVR1 protein inhibitors; Hepcidin modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Iron overload
- No development reported Anaemia; Fibrodysplasia ossificans progressiva
Most Recent Events
- 28 Apr 2025 No recent reports of development identified for preclinical development in Anaemia in USA
- 28 Oct 2023 No recent reports of development identified for preclinical development in Fibrodysplasia-ossificans-progressiva in USA (PO)
- 09 Jun 2021 Pharmacodynamics data from preclinical studies in Iron overload presented at the 26th Congress of the European Haematology Association (EHA-2021)